Company Overview
| Stock Name | Jacobio-B |
|---|---|
| Stock Code | 01167 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 臨床階段製藥公司,專注於創新腫瘤療法的自主發現和開發,主要開發變構SHP2抑制劑、KRAS抑制劑等小分子候選藥物。 |
| Listing Date | 2020-12-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區科創六街88號F2樓 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40層 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.jacobiopharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 14.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 300 shares |
| Entry Threshold | HK$ 4,200 |
| Par Value | To be extracted |
| Offer Period | 2020-12-09 to 2020-12-14 |
| Global Offering Shares | 96,476,100 shares |
| HK Public Offer Shares (Initial) | 9,648,000 shares (10.0%) |
| Public Offer Lots (Initial) | 32,160lots (Pool A16,080lots,Pool B16,080lots) |
| International Placing Shares (Initial) | 86,828,100 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 759,653,880 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 34.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,350,665,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 300 | HK$ 4,200 |
| 2 lots | 600 | HK$ 8,400 |
| 3 lots | 900 | HK$ 12,600 |
| 4 lots | 1,200 | HK$ 16,800 |
| 5 lots | 1,500 | HK$ 21,000 |
| 6 lots | 1,800 | HK$ 25,200 |
| 7 lots | 2,100 | HK$ 29,400 |
| 8 lots | 2,400 | HK$ 33,600 |
| 9 lots | 2,700 | HK$ 37,800 |
| 10 lots | 3,000 | HK$ 42,000 |
| 15 lots | 4,500 | HK$ 63,000 |
| 20 lots | 6,000 | HK$ 84,000 |
| 25 lots | 7,500 | HK$ 105,000 |
| 30 lots | 9,000 | HK$ 126,000 |
| 35 lots | 10,500 | HK$ 147,000 |
| 40 lots | 12,000 | HK$ 168,000 |
| 45 lots | 13,500 | HK$ 189,000 |
| 50 lots | 15,000 | HK$ 210,000 |
| 100 lots | 30,000 | HK$ 420,000 |
| 150 lots | 45,000 | HK$ 630,000 |
| 200 lots | 60,000 | HK$ 840,000 |
| 250 lots | 75,000 | HK$ 1,050,000 |
| 300 lots | 90,000 | HK$ 1,260,000 |
| 350 lots | 105,000 | HK$ 1,470,000 |
| 400 lots | 120,000 | HK$ 1,680,000 |
| 450 lots | 135,000 | HK$ 1,890,000 |
| 500 lots | 150,000 | HK$ 2,100,000 |
| 1,000 lots | 300,000 | HK$ 4,200,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 450,000 | HK$ 6,300,000 |
| 2,000 lots | 600,000 | HK$ 8,400,000 |
| 2,500 lots | 750,000 | HK$ 10,500,000 |
| 3,000 lots | 900,000 | HK$ 12,600,000 |
| 3,500 lots | 1,050,000 | HK$ 14,700,000 |
| 4,000 lots | 1,200,000 | HK$ 16,800,000 |
| 4,500 lots | 1,350,000 | HK$ 18,900,000 |
| 5,000 lots | 1,500,000 | HK$ 21,000,000 |
| 7,000 lots | 2,100,000 | HK$ 29,400,000 |
| 9,000 lots | 2,700,000 | HK$ 37,800,000 |
| 13,000 lots | 3,900,000 | HK$ 54,600,000 |
| 16,080 lots | 4,824,000 | HK$ 67,536,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 4.35B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +123% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 10,635,154,320 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 截至2019年12月31日止年度,虧損人民幣425.8百萬元 |
| Period-End Cash Balance | 人民幣314.3百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Balance Sheet
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Cash and cash equivalents | 420,833 | 314,338 | 405,481 |
| Total current assets | 425,031 | 318,084 | 414,451 |
| Total assets | 473,596 | 363,327 | 455,723 |
| Total current liabilities | 17,965 | 45,721 | 34,316 |
| Total liabilities | 570,841 | 833,405 | 1,738,898 |
| Total equity | -97,245 | -470,078 | -1,283,175 |
| Equity attributable to owners | -95,365 | -469,809 | -1,283,189 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | -79,893 | -113,025 |
| Net cash from investing activities | 14,584 | -273 |
| Net cash from financing activities | 356,827 | 929 |
| Net increase in cash | 291,518 | -112,369 |
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 14.42 |
|---|---|
| First Day Open | HK$ 15.98 |
| First Day Change | 3.00% |
| First Day Volume | 63740700.0 |
| First Day Turnover | 1022840000.0 |
| Use of Proceeds | 1、約88.0%,或143.4百萬美元(1,111.5百萬港元),將主要用于產品的臨床開發及商業化;
2、約8.0%,或13.0百萬美元(101.0百萬港元)將用于建造符合GMP標準的內部生產設施;
3、約4.0%,或6.5百萬美元(50.5百萬港元)將用于我們的一般企業及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (2)
Joint Lead Managers (2)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | HBC Asia Healthcare Opportunities V LLC | 77,515,200 HKD | — | 5.74% | — | 6 months | 2021-06-21 |
| 2 | LAV Prime Limited | 116,272,800 HKD | — | 8.61% | — | 6 months | 2021-06-21 |
| 3 | Matthews Asia Funds | 116,272,800 HKD | — | 8.61% | — | 6 months | 2021-06-21 |
| 4 | Octagon Investments Master Fund LP | 77,515,200 HKD | — | 5.74% | — | 6 months | 2021-06-21 |
| 5 | Sage Partners Master Fund | 38,757,600 HKD | — | 2.87% | — | 6 months | 2021-06-21 |
| 6 | Superstring Capital Master Fund LP | 38,757,600 HKD | — | 2.87% | — | 6 months | 2021-06-21 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 王印祥 | — |
| Company Secretary | 薛青、楊靜文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王印祥及其一致行動人士持股約36.48%;BioEngine Capital Holding Limited持股約12.94%;晟德大藥廠股份有限公司持股約15.64%;Qiming Venture Partners相關基金合計約10.77%;HH SPR-III Holdings Limited約7.49%。 |
|---|




